Up to £100 million will be invested
An Isle of Man life science investment company has launched a new global investment fund, focusing on the therapeutic sector.
Mann Bioinvest, chaired by Jim Mellon, says Mann Bio Pathfinder IC is its second life sciences vehicle and will be managed by chief investment officer Andy Smith.
The fund will invest £100 million in drug development, with a minimum investment of £1,000,000.
The fund will look for life science companies with innovative and specialty products with the best chance of clinical, regulatory and commercial success.
It says it aims to make long-term investments in biotechnology, pharmaceuticals, medical devices and diagnostics.
In a statement, the firm says the sector as a whole has major long-term potential with extra value from a long-term approach to early-stage companies.
And it says an ageing population means there’s more money to be made from both private and public healthcare systems.
Bank blames significant drop in customer numbers for decision to close branch
Port Erin Commissioners agree unanimously to support Co-Op planning application
Time to 'take a breath and look again' at investing in film industry says MHK
'Ideal time' to match derelict sites in Ramsey with investors
